Department of Otolaryngology-Head & Neck Surgery, Al Nahdha Hospital, Oman.
Laryngoscope. 2011 Oct;121(10):2081-9. doi: 10.1002/lary.22165. Epub 2011 Sep 6.
Describe our technique for endoscopic transpterygoid nasopharyngectomy and support its feasibility with our early clinical outcomes.
Our endoscopic technique comprises an extended inferomedial maxillectomy, mobilization of the pterygopalatine fossa, removal of the pterygoid plates and Eustachian tube to access the posterolateral nasopharynx. Control of the parapharyngeal and petrous segments of the internal carotid artery is the keystone of the approach.
Various histopathologies were treated, including epidermoid carcinomas (n = 9), lymphoepithelioma (n = 1), adenoid cystic carcinoma (n = 5), adenocarcinoma (n = 2), mucoepidermoid carcinoma (n = 2), and sarcoma (n = 1). Negative microscopic margins were obtained in 95% (19/20) of patients. No perioperative mortality, cerebral spinal fluid (CSF) leak, meningitis, or cerebrovascular accident was encountered; however, one patient suffered an internal carotid artery (ICA) injury, without permanent sequelae. All but one patient received adjuvant therapy (external and/or stereotactic radiotherapy with or without chemotherapy). Follow-up ranged from 15 to 68 months (mean = 33). Overall survival was 45% (9/20) and local control was 65% (13/20).
Endoscopic transpterygoid nasopharyngectomy for primary and recurrent nasopharyngeal malignancies is feasible and safe in properly selected patients. Preliminary outcomes compare to that of conventional techniques. Endoscopic resections, however, are demanding; they require specialized equipment and a team versed in endoscopic oncologic surgery. Long-term follow-up and reproducibility remain undefined.
描述我们经内镜经翼突入路鼻咽切除术的技术,并通过我们的早期临床结果支持其可行性。
我们的内镜技术包括扩展的中内侧上颌骨切除术、翼腭窝的游离、翼板和咽鼓管的切除以进入鼻咽的后外侧。颈内动脉咽旁和岩骨段的控制是该入路的关键。
治疗了各种组织病理学类型,包括表皮样癌(n=9)、淋巴上皮瘤(n=1)、腺样囊性癌(n=5)、腺癌(n=2)、黏液表皮样癌(n=2)和肉瘤(n=1)。95%(19/20)的患者获得了显微镜下阴性的切缘。无围手术期死亡、脑脊液(CSF)漏、脑膜炎或脑血管意外发生;然而,有 1 名患者发生颈内动脉(ICA)损伤,但无永久性后遗症。除 1 例患者外,所有患者均接受了辅助治疗(外照射和/或立体定向放疗联合或不联合化疗)。随访时间为 15 至 68 个月(平均=33)。总生存率为 45%(9/20),局部控制率为 65%(13/20)。
对于原发性和复发性鼻咽恶性肿瘤,经内镜经翼突入路鼻咽切除术在适当选择的患者中是可行和安全的。初步结果与传统技术相当。然而,内镜切除术要求较高;它们需要专门的设备和一支精通内镜肿瘤手术的团队。长期随访和可重复性仍未确定。